Fintel reports that on August 31, 2023, Cantor Fitzgerald reiterated coverage of Soleno Therapeutics (NASDAQ:SLNO) with a Overweight recommendation.
Analyst Price Forecast Suggests 146.18% Upside
As of August 31, 2023, the average one-year price target for Soleno Therapeutics is 12.58. The forecasts range from a low of 8.08 to a high of $19.95. The average price target represents an increase of 146.18% from its latest reported closing price of 5.11.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Soleno Therapeutics is 0MM. The projected annual non-GAAP EPS is -1.87.
What is the Fund Sentiment?
There are 5 funds or institutions reporting positions in Soleno Therapeutics. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to SLNO is 0.79%, an increase of 91.76%. Total shares owned by institutions decreased in the last three months by 0.00% to 245K shares.
What are Other Shareholders Doing?
Birchview Capital holds 245K shares representing 2.45% ownership of the company. No change in the last quarter.
Soleno Therapeutics Background Information
(This description is provided by the company.)
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program.
Additional reading:
- Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors
- Amendment to lease agreement, dated April 24, 2023, by and between Soleno Therapeutics, Inc. and Hudson Towers at Shore Center, LLC
- Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
